Generate Biomedicines (NASDAQ:GENB) ended a shortened trading week above its initial public offering price, a milestone that investors watched closely after the stock's February debut. Shares closed Friday at $16.47, surpassing the $16 IPO price, and were quoted at $16.95 in after-hours trading. The stock gained 13.7% from its June 18 close of $14.49 through Friday, marking three consecutive closes above $16.
Volume on Friday reached 4.10 million shares, approximately 4.4 times the average daily volume of 934,290. The heavy trading came as U.S. markets closed for the weekend, with Nasdaq regular trading running Monday through Friday from 9:30 a.m. to 4 p.m. Eastern. The exchange will also be closed Friday, July 3, for Independence Day observed, leaving four regular sessions for GENB to maintain the $16 level.
Generate raised $400 million at $16 per share in its February IPO, opening at $15 on Nasdaq with a valuation of $1.91 billion, according to Reuters. At Friday's close, the company's market capitalization stood at approximately $2.11 billion, reflecting investor optimism despite ongoing clinical and financial uncertainties.
The company's financial position remains a key focus. As of March 31, Generate held $516.6 million in cash, cash equivalents, and marketable securities, or about $4.03 per share based on 128.2 million shares outstanding. With first-quarter operating cash use of $80.4 million, that cash pile would last roughly 6.4 quarters if spending remained flat. The company stated that current funds can support operations into the first half of 2028, but it also acknowledged the need for additional capital for long-term operations.
Clinical risks accompany the financial picture. Generate's 10-Q filing revealed that the FDA and European Medicines Agency recommended a dose-ranging trial for GB-0895 in severe asthma, and the company noted that moving directly into Phase 3 with a single dose carries higher risk. Generate is testing a 300 mg subcutaneous dose administered every six months. CEO Mike Nally said in May that the company is advancing GB-0895 in Phase 3 for severe asthma and Phase 1b for COPD. Additionally, clinical trial sites have been activated for GB-4362, with first patient dosing expected in mid-2026, while GB-5267 is anticipated to dose its first patient in the second half of 2026.
Revenue remains limited to collaboration agreements, not product sales. Generate recorded $7.2 million in first-quarter collaboration revenue, down from $8.8 million a year earlier. Of that, $6.5 million came from its agreement with Novartis (NYSE:NVS) and $0.7 million from Amgen (NASDAQ:AMGN).
The stock's advance occurred amid a broader sector rally. The State Street SPDR S&P Biotech ETF (NYSEARCA:XBI) closed 2.5% higher on Friday and was up more than 13% in June, according to Barron's. Mizuho healthcare sector specialist Jared Holz noted that XBI had moved higher a record 12 of 13 months and remarked that the sector has not traded this consistently well in years—arguably ever.
Generate President and CFO Jason Silvers told Reuters at the IPO that machine learning provides access to tools that traditional drug discovery does not, adding that the timing is favorable as the company has multiple initiatives requiring capital. IPOX Research Associate Lukas Muehlbauer cautioned before the listing that valuation would be the main focus, and investors would seek proof that AI changes drug development, given that no fully AI-discovered drug has yet received FDA approval.
